Antiphospholipid Syndrome

Antiphospholipid syndrome (APS) is an acquired autoimmune thrombophilia in which circulating antiphospholipid antibodies increase the risk of both arterial and venous thrombosis and cause a distinct pattern of pregnancy morbidity — recurrent early miscarriage, later fetal loss, or placental-insufficiency-related complications such as severe preeclampsia and intrauterine growth restriction.^[1] The diagnosis is never made from a single positive antibody test: it requires at least 1 qualifying clinical event (a confirmed thrombosis, or one of the defined pregnancy-morbidity patterns) together with a persistently positive antiphospholipid antibody result — lupus anticoagulant, anticardiolipin antibody, or anti-beta-2-glycoprotein I antibody — confirmed on 2 separate occasions at least 12 weeks apart.^[1] APS occurs either alone (primary APS) or alongside another autoimmune disease, most often systemic lupus erythematosus (secondary APS) — see the Systemic Lupus Erythematosus chapter for the SLE-specific overlap and its background hydroxychloroquine therapy.^[2] The single highest-value pharmacology point in this chapter is that warfarin, not a direct oral anticoagulant (DOAC), is the guideline-recommended standard of care for APS-associated thrombosis — randomized trial evidence shows a DOAC performs worse than warfarin in this specific population, especially triple-positive APS, and current guidance recommends against using a DOAC here even though DOACs are preferred first-line therapy for most other causes of venous thromboembolism.^[3][2]

A rare, distinct, and rapidly life-threatening variant — catastrophic APS — produces thrombosis in 3 or more organs developing over days rather than the single-event pattern typical of standard APS; see Red Flags & Refer.

• Systemic lupus erythematosus or another autoimmune connective tissue disease (secondary APS) — see the Systemic Lupus Erythematosus chapter for the overlap.
• Female sex, particularly during reproductive years.
• A triple-positive antibody profile (lupus anticoagulant, anticardiolipin, and anti-beta-2-glycoprotein I all positive) — the single strongest predictor of future thrombotic and obstetric events.
• A personal history of thrombosis or pregnancy morbidity consistent with APS.
• Conventional prothrombotic risk factors that compound APS-related risk rather than replacing it as the explanation — smoking, obesity, immobilization, recent surgery, and estrogen-containing contraception or hormone therapy (see Non-Pharmacologic Treatment).
• Pregnancy and the postpartum period.
• Family history of APS or another autoimmune disease.
• Rarely, transient antiphospholipid antibody positivity associated with certain infections or medications — distinguished from true APS by the absence of a qualifying clinical event and by non-persistence on repeat testing.

Diagnostic criteria (international consensus / revised Sapporo)

APS is diagnosed clinically using the international consensus (revised Sapporo) criteria: at least 1 clinical criterion plus at least 1 laboratory criterion, with the laboratory result confirmed positive on 2 or more occasions at least 12 weeks apart.^[1]

Antibody testing caveats

Order all 3 tests together whenever possible — lupus anticoagulant, anticardiolipin (IgG and IgM), and anti-beta-2-glycoprotein I (IgG and IgM) — since the antibody profile itself is a risk-stratification tool, not just a yes/no diagnostic gate (see below). Avoid testing during an acute thrombotic event or acute illness where possible: transient, clinically insignificant antibody positivity can occur around acute thrombosis, and a result obtained during the acute event should be confirmed with repeat testing once the patient has recovered, in addition to the mandatory 12-week repeat. Anticoagulation can interfere with lupus anticoagulant assays — heparin and warfarin both affect clot-based testing, and a DOAC can produce a false-positive lupus anticoagulant result; involve the coagulation laboratory before ordering, or time testing to a period off interfering anticoagulation where clinically feasible.

Risk stratification: triple positivity

Patients positive for all 3 antibody types — lupus anticoagulant, anticardiolipin, and anti-beta-2-glycoprotein I — are classified as triple-positive and carry the highest risk of both thrombotic recurrence and treatment failure with a DOAC; this profile is central to the anticoagulant-selection decision in Choose Initial Treatment.^[2][3]

Primary versus secondary APS

APS occurring in isolation is termed primary APS; APS occurring alongside another autoimmune disease — most often systemic lupus erythematosus, and less often another connective tissue disease — is termed secondary APS. Screen every newly diagnosed APS patient for SLE, and vice versa (see the Systemic Lupus Erythematosus chapter), since the distinction changes the overall care plan (background hydroxychloroquine, SLE-specific monitoring) even though the anticoagulation approach to a given thrombotic or obstetric event is the same either way.

2023 ACR/EULAR classification criteria

A newer, more specific classification system — requiring a qualifying clinical event plus at least 1 positive antibody test within 3 years, then an additive weighted point score across 6 clinical domains (macrovascular venous thromboembolism, macrovascular arterial thrombosis, microvascular disease, obstetric morbidity, cardiac valve disease, and hematologic/thrombocytopenia) and 2 laboratory domains (lupus anticoagulant, and solid-phase anticardiolipin/anti-beta-2-glycoprotein I testing weighted by titre) — classifies a patient as having APS once both the clinical and laboratory domains individually reach at least 3 points.^[4] It was developed primarily to create a more specific cohort for research and clinical trials (specificity 99% versus 86% for the original criteria, at some cost to sensitivity), and its per-item point weighting requires the full published criteria set rather than a simple flat point-sum, so it is presented here as a teaching reference rather than an interactive calculator — the clinical-plus-persistent-antibody framework above remains what is used for everyday bedside diagnosis.^[4]

Catastrophic APS

A separate, rare, rapidly progressive variant defined by thrombosis affecting 3 or more organs, developing over days (rather than the single-event pattern typical of standard APS), with laboratory confirmation of antiphospholipid antibodies and, where obtained, histopathological confirmation of small-vessel occlusion — mortality is high without immediate recognition and treatment (see Red Flags & Refer and Choose Initial Treatment).^[2]

• Prevent first and recurrent thrombosis, matched to the vascular bed (venous versus arterial) and antibody risk profile.
• Support a successful pregnancy and live birth in obstetric APS.
• Recognize and treat catastrophic APS immediately when it occurs.
• Minimize bleeding risk from anticoagulation itself.
• Manage the SLE overlap and shared cardiovascular risk factors in secondary APS.
• Avoid iatrogenic harm — most importantly, avoid a direct oral anticoagulant as the choice for APS-associated thrombosis.

• Smoking cessation — an independent, modifiable thrombosis risk factor that compounds APS-related risk.
• Avoid estrogen-containing contraception and estrogen-containing hormone therapy in anyone with a positive antiphospholipid antibody profile, regardless of whether they meet full APS criteria — use a non-hormonal method or a progestin-only method instead.
• Aggressively manage conventional cardiovascular risk factors — blood pressure, lipids, glucose, and weight — since these compound thrombotic risk on top of APS itself.
• Avoid unnecessary prolonged immobilization; use mechanical and/or pharmacologic VTE prophylaxis around any hospitalization or surgery, planned well in advance with the treating specialist for anyone on chronic warfarin who needs perioperative bridging.
• Patient education: medical alert identification stating the APS diagnosis and current anticoagulant, and a clear individualized action plan for suspected new thrombosis or, in a pregnant patient, an obstetric emergency.
• Early ambulation after any thrombotic event, as tolerated, once anticoagulation is therapeutic.
• For women of reproductive age: discuss family planning and warfarin's teratogenicity proactively, well before an unplanned pregnancy occurs (see Special Populations).

Pregnancy

Breastfeeding

Warfarin, unfractionated heparin, LMWH, and low-dose ASA are all compatible with breastfeeding — warfarin's placental-crossing teratogenicity concern is specific to pregnancy and does not apply postpartum, since only clinically insignificant amounts of warfarin pass into breast milk. A DOAC is not recommended during breastfeeding, independent of the separate reason it is avoided in APS specifically.

Secondary APS (SLE overlap)

Confirm whether SLE or another autoimmune disease coexists at diagnosis, and vice versa (see the Systemic Lupus Erythematosus chapter) — hydroxychloroquine background therapy, SLE-specific monitoring, and shared cardiovascular risk-factor management all apply in addition to the APS-specific anticoagulation plan above; the anticoagulation approach to a given thrombotic or obstetric event does not otherwise differ between primary and secondary APS.

Renal impairment

Dose-reduce LMWH and monitor anti-Xa levels as renal function falls; unfractionated heparin, with no renal clearance dependence, is preferred once impairment is severe. Warfarin dosing is not renally adjusted, but bleeding risk still rises with reduced renal function — monitor INR at least as frequently as usual.

Older adults

Bleeding risk on warfarin rises with age — this is a reason for closer INR monitoring, not a reason to substitute a DOAC in a patient with APS-associated thrombosis.

Perioperative management

Plan warfarin interruption and heparin/LMWH bridging with the treating specialist well in advance of any planned surgery or invasive procedure — do not stop warfarin without a bridging plan in a patient with APS, given the elevated rebound thrombosis risk in this population.

Pediatric APS

Rare in children; refer to pediatric hematology/rheumatology rather than extrapolating adult dosing directly.

Warfarin: check INR daily or every other day during initiation, then space out to every 2-4 weeks once stable, using the same general schedule as for VTE (see the Venous Thromboembolism chapter); confirm time-in-therapeutic-range at each visit, since a technically "on warfarin" patient with poor time-in-range is a common, correctable cause of apparent treatment failure. LMWH: monitor platelet count for HIT surveillance, particularly in the first 1-2 weeks of exposure; monitor anti-Xa levels in pregnancy and renal impairment. Every patient: reassess bleeding risk against thrombotic risk at every visit rather than assuming a fixed indefinite regimen needs no further review; screen for new or evolving SLE/autoimmune features at least annually; monitor blood pressure, lipids, and glucose given the compounding cardiovascular risk; monitor platelet count periodically, since new or worsening thrombocytopenia can be an early catastrophic-APS warning sign in an acutely unwell patient; in a current or recently pregnant patient, follow the fetal growth/placental-function monitoring schedule set by the obstetric team; and confirm that antibody-positive but not-yet-diagnostic patients are actually brought back for the mandatory 12-week repeat test before a diagnosis is either confirmed or excluded.

1. Recurrent thrombosis on warfarin: before assuming true treatment failure, confirm adherence and confirm the INR has genuinely been in the therapeutic range over time (not just checked once), and screen for a new interacting drug.
2. Confirmed adherent, genuinely therapeutic INR, with recurrence: add low-dose ASA, increase the INR target (commonly to 3-4), or switch to therapeutic-dose LMWH - specialist-directed.
3. Recurrent pregnancy loss despite ASA plus prophylactic-dose heparin: confirm adherence and dosing, reassess for an additional non-APS cause of pregnancy loss, and consider increasing heparin to a therapeutic dose or adding hydroxychloroquine under specialist direction.
4. A patient found to have been using a DOAC for APS-associated thrombosis: switch to warfarin promptly rather than continuing the DOAC, even in the absence of a new event, given the trial evidence of inferior protection.
5. Rapidly evolving multi-organ dysfunction in a patient with known or suspected APS: treat as possible catastrophic APS and escalate emergently rather than working through the standard treatment-failure sequence above.
6. Major bleeding on anticoagulation: hold the agent, apply local hemostatic measures, use vitamin K and/or prothrombin complex concentrate for warfarin reversal per institutional major-bleeding protocol, and reassess the net risk-benefit of resuming therapy once the patient is stable.

• Using a DOAC instead of warfarin for APS-associated thrombosis, particularly in triple-positive or arterial disease.
• Diagnosing APS from a single positive antibody test without confirming persistence on a repeat test at least 12 weeks later.
• Ordering lupus anticoagulant testing without accounting for interference from current anticoagulation (heparin, warfarin, or a DOAC).
• Continuing warfarin into a pregnancy instead of switching to LMWH before conception or immediately on confirming an unplanned pregnancy.
• Treating obstetric APS with aspirin alone instead of the combination of low-dose ASA plus prophylactic-dose heparin.
• Stopping postpartum anticoagulation too early - the postpartum period carries the highest VTE risk of the pregnancy episode.
• Missing catastrophic APS in a patient with known APS who develops rapid multi-organ dysfunction, and treating with anticoagulation alone instead of the full combination regimen.
• Continuing estrogen-containing contraception or hormone therapy in an antiphospholipid antibody-positive patient.
• Interrupting warfarin perioperatively without a bridging plan in a patient with APS.
• Withholding anticoagulation in a patient with a genuine thrombotic indication because of mild APS-related thrombocytopenia alone.

How to use this table: Doses are adult doses and require patient-specific confirmation, including renal/hepatic adjustment and, in pregnancy, coordination with the obstetric team. Select any drug name to open its complete Pharmasist Drug Database page.

Vitamin K Antagonist (guideline-preferred for APS-associated thrombosis)

Antiplatelet

Antimalarial (adjunct)

Low Molecular Weight Heparins

Preferred parenteral anticoagulant for obstetric APS and for thrombotic APS during pregnancy - does not cross the placenta, unlike warfarin.

Unfractionated Heparin

Not recommended for APS-associated thrombosis

A randomized trial in high-risk (triple-positive) APS stopped early because rivaroxaban produced significantly more thromboembolic events than warfarin, with no bleeding advantage.<cite data-reference-id="dff1f4d2-db79-4067-8961-5c78114665f2"></cite> Current guidance recommends against a DOAC for APS-associated thrombosis, particularly in triple-positive or arterial disease.<cite data-reference-id="fa95cfc3-c2e1-4771-8e84-3201f11790a6"></cite>

Catastrophic APS - emergency combination therapy

Used together, alongside therapeutic-dose heparin - never as monotherapy - and alongside treatment of any precipitating factor.

Warfarin reversal